Novo Nordisk: targets confirmed with strong Q3

(CercleFinance.com) - Novo Nordisk, the world's leading diabetes treatment company, reported higher-than-expected 9m operating profit on Thursday thanks to the success of its anti-obesity treatment Wegovy.


The Danish laboratory's operating profit rose by 31% to 75.8bn DKK in the first nine months of the year, with a 37% increase at constant exchange rates.

Sales totalled 166.4bn DKK, up 29% y-o-y, or +33% at constant exchange rates.

A recent study showed that Wegovy, whose primary function is to help people suffering from obesity to lose weight, has other virtues, principally a 20% reduction in the risk of cardiovascular accidents in overweight people.

Following this publication, the group confirmed its annual targets, which it raised last month, still targeting sales growth of 32% to 38% at constant exchange rates, and an expected 40%-to-46% increase in operating profit.


Copyright (c) 2023 CercleFinance.com. All rights reserved.